Prosecution Insights
Last updated: November 04, 2026
Application No. 18/948,158

USE OF CLADRIBINE FOR TREATING AUTOIMMUNE NEUROMUSCULAR DISEASE

Non-Final OA §DOUBLEPATENT
Filed
Nov 14, 2024
Priority
Jul 21, 2017 — GB 1711800.1 +2 more
Examiner
KRISHNAN, GANAPATHY
Art Unit
1693
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Chord Therapeutics SA
OA Round
1 (Non-Final)
53%
Grant Probability
Moderate
1-2
OA Rounds
1y 2m
Est. Remaining
54%
With Interview

Examiner Intelligence

Grants 53% of resolved cases
53%
Career Allowance Rate
596 granted / 1130 resolved
-7.3% vs TC avg
Minimal +1% lift
Without
With
+1.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
53 currently pending
Career history
1190
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
39.6%
-0.4% vs TC avg
§102
13.8%
-26.2% vs TC avg
§112
25.0%
-15.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1130 resolved cases

Office Action

§DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-6 are pending in the application. Preliminary amendment filed 25 June 2025. Priority This application is a continuation of 16/632,245 filed 01/17/2020, now US Patent No. 12171775, which is a 371 of PCT/GB2018/051801 filed 06/28/2018. This application claims foreign priority to UNITED KINGDOM 1711800.1 filed 07/21/2017, under 35 U.S.C. 119(a)-(d). The certified copy of the priority document has been filed in parent application 16/632,245. The parent application UNITED KINGDOM 1711800.1 to which priority is claimed is seen to provide adequate support under 35 U.S.C. 112 for claims 1-6 of this application. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). The USPTO Internet website contains Terminal Disclaimer forms which may be used. Please visit www.uspto.gov/forms/. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claims 1-6 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-6 of U.S. Patent No. 12,171,775 (‘775). Although the claims at issue are not identical, they are not patentably distinct from each other because: Instant Claims 1and 6 are drawn to a method of treating or ameliorating acetylcholine receptor antibody positive myasthenia gravis in a subject via administration of an effective amount of 2-chloro2-deoxyadenosine (cladribine) or a pharmaceutically acceptable salt thereof. Dependent claims 2-5 and claim 6 recite dosages, and time period of administration of the active agent. Claim 1 and 6 of ‘775 are drawn to a method of treating or ameliorating myasthenia gravis in a subject via administration of an effective amount of 2-chloro2-deoxyadenosine (cladribine) or a pharmaceutically acceptable salt thereof. Dependent claims 2-5 and claim 6 recite dosages, and time period of administration of the active agent. Claims 1-6 of ‘775 differ from the instant claims in that the instant claims are drawn to treating or ameliorating acetylcholine receptor antibody positive myasthenia gravis, whereas the claims of ‘775 recite myasthenia gravis. However, it would have been obvious to one of ordinary skill in the art before the filing date of the instant invention that the method of ‘775 could be successfully employed in the instant method since the method of ‘775 is drawn to treating myasthenia gravis in a patient broadly, which includes the instant patient population too. The use of known active agent in a method of treatment taught in the prior art is not seen to render the instantly claimed method unobvious over the art. Once the method has been shown to be old, the burden is on the applicant to present reason or authority for believing that the method of the prior art is different and will not work for the instant patient population. Conclusion Pending claims 1-6 are rejected Any inquiry concerning this communication or earlier communications from the examiner should be directed to GANAPATHY KRISHNAN whose telephone number is (571)272-0654. The examiner can normally be reached M-F 8.30am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GANAPATHY KRISHNAN/Primary Examiner, Art Unit 1693
Read full office action

Prosecution Timeline

Nov 14, 2024
Application Filed
Jun 25, 2025
Response after Non-Final Action
Oct 14, 2026
Examiner Interview (Telephonic)
Oct 20, 2026
Non-Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778979
TREATMENT OF PATIENTS UNDER ANTIPLATELET MEDICATION EXPERIENCING ACUTE BLEEDING COMPLICATIONS DURING/AFTER SURGERY
4y 10m to grant Granted Nov 03, 2026
Patent 12781215
NUCLEIC ACID PREPARATION COMPOSITIONS AND METHODS
2y 3m to grant Granted Nov 03, 2026
Patent 12767682
Process For Purifying Sialylated Oligosaccharides
2y 9m to grant Granted Oct 20, 2026
Patent 12766162
ORAL SOLUTION BASED ON CITICOLINE AND NICOTINAMIDE FOR USE IN THE TREATMENT OF GLAUCOMA
2y 11m to grant Granted Oct 20, 2026
Patent 12735695
AUTOMATED AND MANUAL METHODS FOR ISOLATION OF EXTRACELLULAR VESICLES AND CO-ISOLATION OF CELL-FREE DNA FROM BIOFLUIDS
5y 11m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
53%
Grant Probability
54%
With Interview (+1.4%)
3y 1m (~1y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1130 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month